- Home
- ENLT vs FOLD Comparison
ENLT vs FOLD Comparison
Compare ENLT & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENLT | FOLD |
|---|---|---|
| Founded | 2008 | 2002 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.5B |
| IPO Year | 2022 | 2006 |
Fundamental Metrics
Financial Performance| Metric | ENLT | FOLD |
|---|---|---|
| Price | $77.10 | $14.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $45.17 | $27.25 |
| AVG Volume (30 Days) | 165.0K | ★ 3.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $403.69 | $20.50 |
| Revenue Next Year | N/A | $18.59 |
| P/E Ratio | $76.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.01 | $5.66 |
| 52 Week High | $81.28 | $14.38 |
Technical Indicators
Market Signals| Indicator | ENLT | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 68.67 | 66.13 |
| Support Level | $34.42 | $14.21 |
| Resistance Level | $81.28 | $14.37 |
| Average True Range (ATR) | 3.10 | 0.03 |
| MACD | 0.22 | -0.04 |
| Stochastic Oscillator | 73.03 | 42.86 |
Price Performance
Historical ComparisonAbout ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.